灯盏生脉胶囊辅助治疗缺血性脑卒中的系统评价与Meta分析
该系统评价与Meta分析纳入14项随机对照试验共5206例缺血性脑卒中患者,评估灯盏生脉胶囊作为辅助治疗的有效性与安全性。结果显示,在常规治疗基础上加用灯盏生脉胶囊可能改善神经功能、生活质量并降低复发率,但多数试验存在高偏倚风险,证据强度较弱,结论尚不确定。
要点
- 灯盏生脉胶囊辅助常规治疗可能改善急性期缺血性脑卒中患者的Barthel指数和神经功能缺损评分。
- 灯盏生脉胶囊可能降低急性期及恢复期/后遗症期缺血性脑卒中患者的复发率。
- 纳入试验未报告严重不良事件,但整体方法学质量高偏倚风险,获益证据不确凿。
核心结论
- 灯盏生脉胶囊在常规治疗基础上可能改善缺血性脑卒中患者的神经功能、生活质量并降低复发率,且似乎 generally safe,但获益证据不确凿,仍需大型严谨试验验证。
研究设计与样本
- 系统评价与Meta分析(PROSPERO注册号CRD42016042914),检索6个电子数据库至2016年5月,纳入14项随机对照试验共5206例参与者。
主要发现
- 急性缺血性脑卒中:加用灯盏生脉胶囊组Barthel指数评分更高(MD 22.37,95%CI 21.34-23.40),神经功能缺损评分更低(MD -3.73,95%CI -5.27至-2.19),复发率更低(RR 0.22,95%CI 0.10-0.46)。
- 恢复期或后遗症期缺血性脑卒中:灯盏生脉胶囊组较安慰剂组在改善生活质量(MD 28.8,95%CI 7.10-50.50)和降低复发率(RR 0.71,95%CI 0.51-0.99)方面更优。
- 无试验报告严重不良事件。
关键数值与推荐
- 急性缺血性脑卒中加用灯盏生脉胶囊对比常规治疗:Barthel指数MD 22.37(95%CI 21.34-23.40),神经功能缺损评分MD -3.73(95%CI -5.27至-2.19),复发率RR 0.22(95%CI 0.10-0.46)。
- 恢复期/后遗症期缺血性脑卒中灯盏生脉胶囊对比安慰剂:生活质量MD 28.8(95%CI 7.10-50.50),复发率RR 0.71(95%CI 0.51-0.99)。
临床怎么用
- 在常规治疗基础上,可考虑对缺血性脑卒中患者(急性期或恢复期/后遗症期)辅助使用灯盏生脉胶囊以改善神经功能、生活质量并降低复发率。
- 临床决策时应告知患者现有证据方法学质量偏低、获益结论尚不确定,需结合个体情况谨慎使用。
局限性
- 多数纳入试验在方法学质量上存在高偏倚风险。
- 证据强度普遍较弱,导致获益结论不确凿。
- 仍需进一步开展大型、严谨的随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The existing eligible randomized controlled trials (RCTs) were critically appraised for the effectiveness and safety of Chinese herbal medicine Dengzhan Shenmai for ischemic stroke. DESIGN: Systematic review and meta-analysis (CRD42016042914, http://www.crd.york.ac.uk/PROSPERO). METHODS: Six electronic databases were searched from inception to May 2016. Risk ratio (RR) and mean difference (MD) with a 95% confidence interval (CI) were used as effect estimates using RevMan 5.3. Meta-analysis was performed where data were available. A summary of finding table was generated by the GRADEpro (version 3.6). RESULTS: We identified 14 RCTs involving 5206 participants. Majority of the included trials were of high risk of bias in methodological quality. For acute ischemic stroke, adding DZSM capsule to conventional therapy achieved higher Barthel Index scores (MD 22.37, 95% CI 21.34-23.40), lower neurological function deficit scores (MD - 3.73, 95% CI -5.27 to -2.19) and lower recurrence rate (RR 0.22, 95% CI 0.10, 0.46). For patients in their convalescence (or sequelae) stage of ischemic stroke, DZSM capsule was superior in improving quality of life (MD 28.8, 95% CI 7.10-50.50) and recurrence rate (RR 0.71, 95% CI 0.51-0.99) compared to placebo. No trials reported serious adverse events. CONCLUSION: DZSM capsule appears to improve neurological function, quality of life, and reduce recurrence rate based on conventional therapy for ischemic stroke. DZSM capsule seems generally safe for clinical application. However, the findings of benefit are inconclusive due to generally weak evidence, and further large, rigorous trials are still warranted.
引用
- Yang XY, Wang LQ, Li JG, et al. Chinese herbal medicine Dengzhan Shengmai capsule as adjunctive treatment for ischemic stroke: A systematic review and meta-analysis of randomized clinical trials. Complement Ther Med. 2017. PMID: 29458937. doi:10.1016/j.ctim.2017.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。